Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

At this time, I would like to welcome everyone to the Q3 2024 Emergent BioSolutions Inc. earnings conference call. All lines ...

The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...

EPS: US$2.16 (up from US$5.09 loss in 3Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

Emergent Biosolutions (EBS) stock rose 14% post-market after the company raised the lower end of its revenue guidance range ...

Emergent BioSolutions expects a 2024 net loss of $203 million-$183 million, down from the previous loss range of $314 million ...

Emergent Biosolutions ( (EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of $2.06. Earnings, adjusted for non-recurring gains, were $1.37 per share. The biopharmaceutical company posted ...

Emergent BioSolutions appointed Dr. Simon Lowry as chief medical officer and head of research and development. CureVac named ...